Evidence map›Paper›PMID 34725968›Full record

ArticleESC heart failure2021

Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure.

Leen Delrue, Marc Vanderheyden, Monika Beles, Pasquale Paolisso, Giuseppe Di Gioia, Riet Dierckx, Sofie Verstreken, Marc Goethals, Ward Heggermont, Jozef Bartunek

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Cardiovascular Disease and Cancer: A Dangerous Liaison.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Leen DelrueCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Marc VanderheydenCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Monika BelesCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Pasquale PaolissoCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Giuseppe Di GioiaCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Riet DierckxCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Sofie VerstrekenCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Marc GoethalsCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Ward HeggermontCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Jozef BartunekCardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.
Onze Lieve Vrouwziekenhuis Hospital · BEUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe investigated the prognostic relevance of serpin peptidase inhibitor, clade A member 3 (SERPINA3) in patients admitted with a de novo or worsened heart failure (HF). METHODS AND

resultsIn the first stage, 83 HF-related left ventricular (LV) transcripts were examined in patients with congestive cardiomyopathy (CCMP, n = 44) who died within 5 years and compared with age-matched and haemodynamically matched CCMP survivors (n = 39) and controls with normal LV function (n = 17). Among 14 differentially expressed transcripts, myocardial gene and circulating SERPINA3 levels were up-regulated in non-survivors vs. survivors (2.40 ± 3.66 vs. 0.36 ± 0.22 units, P < 0.01 and 334.7 ± 138.7 vs. 228.2 ± 83.1 μg/mL, P < 0.01, respectively). While no significant transmyocardial gradient was detected, cytokine stimulation of human endothelial cells induced SERPINA3 secretion. In an independent validation cohort with a de novo or worsened HF (n = 387), circulating SERPINA3 levels > 316 μg/mL were associated with increased all-cause mortality {hazard ratio [HR] [95% confidence interval (CI)]: 2.4 [1.5-3.9], P = 0.0002} and its composite with unplanned cardiovascular readmission [HR (95% CI): 2.0 (1.2-3.3), P = 0.004]. Patients with elevated SERPINA3 levels and elevated either N-terminal pro brain natriuretic peptide or ST2 showed worse freedom from both endpoints. In a multivariate analysis, including established clinical risk factors, SERPINA3 remained independent predictor of all-cause mortality together with age, gender, ST2, glomerular filtration, and pulmonary capillary wedge pressure.

conclusionIn patients with a de novo or worsened HF, increased SERPINA3 levels > 316 μg/mL are associated with increased mortality or unplanned cardiac readmission. Elevated SERPINA3 levels on top of established clinical predictors appear to identify a subgroup of HF patients at higher mortality risk. Prospective studies should further validate its value in prognostic stratification of HF.

Indexed as

Heart FailureSerpinsEndothelial CellsHumansPrognosisProspective StudiesVentricular Function, LeftSERPINA3 protein, humanSerpinsBiomarkersCardiomyopathyHeart failureInflammationPrognosis

Identifiers

PMID34725968
PMCPMC8712810
OpenAlexW3208337367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.